glenzocimab (ACT 017) - Acticor Biotech
https://apps.congrex.com/esoc2024/en-GB/pag/presentation/365400
 
Martin Köhrmann1; Natan Bornstein2; Helle Klingenber Iversen3; Dheeraj Kalladka4; Georgi Krastev5; Carlos A. Molina6; André Peeters7; Daniel Sanak8; Igor Sibon9; James Grotta10; J.Berrouschot(DE); J.Serena(SP); G.AVENARD(FR); S.BINAY(FR); S.BOUGAMRA(FR); A.COMENDUCCI(FR); A.MEILHOC(FR); Y.Pletan(FR); E.Toledano(FR); J.Grouin(FR); ACTISAVE Study Group
 
Apr 27, 2024
 
Prev Next